280 related articles for article (PubMed ID: 25848273)
1. Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy.
Chen Y; Wang X; Liu T; Zhang DS; Wang Y; Gu H; Di W
Int J Nanomedicine; 2015; 10():2579-94. PubMed ID: 25848273
[TBL] [Abstract][Full Text] [Related]
2. A mesoporous silica nanoparticle--PEI--fusogenic peptide system for siRNA delivery in cancer therapy.
Li X; Chen Y; Wang M; Ma Y; Xia W; Gu H
Biomaterials; 2013 Jan; 34(4):1391-401. PubMed ID: 23164421
[TBL] [Abstract][Full Text] [Related]
3. Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier.
Chen Y; Gu H; Zhang DS; Li F; Liu T; Xia W
Biomaterials; 2014 Dec; 35(38):10058-69. PubMed ID: 25277774
[TBL] [Abstract][Full Text] [Related]
4. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
Lu ZX; Liu LT; Qi XR
Int J Nanomedicine; 2011; 6():1661-73. PubMed ID: 21904456
[TBL] [Abstract][Full Text] [Related]
5. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
6. Polyetherimide-grafted Fe₃O₄@SiO2₂ nanoparticles as theranostic agents for simultaneous VEGF siRNA delivery and magnetic resonance cell imaging.
Li T; Shen X; Chen Y; Zhang C; Yan J; Yang H; Wu C; Zeng H; Liu Y
Int J Nanomedicine; 2015; 10():4279-91. PubMed ID: 26170664
[TBL] [Abstract][Full Text] [Related]
7. Dual-Targeting Multifuntional Mesoporous Silica Nanocarrier for Codelivery of siRNA and Ursolic Acid to Folate Receptor Overexpressing Cancer Cells.
Zheng G; Shen Y; Zhao R; Chen F; Zhang Y; Xu A; Shao J
J Agric Food Chem; 2017 Aug; 65(32):6904-6911. PubMed ID: 28771340
[TBL] [Abstract][Full Text] [Related]
8. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
9. Characterization of polyethylene glycol-grafted polyethylenimine and superparamagnetic iron oxide nanoparticles (PEG-g-PEI-SPION) as an MRI-visible vector for siRNA delivery in gastric cancer in vitro and in vivo.
Chen Y; Lian G; Liao C; Wang W; Zeng L; Qian C; Huang K; Shuai X
J Gastroenterol; 2013 Jul; 48(7):809-21. PubMed ID: 23179610
[TBL] [Abstract][Full Text] [Related]
10. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis.
Ding Y; Wang Y; Zhou J; Gu X; Wang W; Liu C; Bao X; Wang C; Li Y; Zhang Q
Biomaterials; 2014 Aug; 35(25):7214-27. PubMed ID: 24875759
[TBL] [Abstract][Full Text] [Related]
11. Polyethylene glycol-poly(ε-benzyloxycarbonyl-l-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma.
Wang G; Gao X; Gu G; Shao Z; Li M; Wang P; Yang J; Cai X; Li Y
Int J Nanomedicine; 2017; 12():3591-3603. PubMed ID: 28533682
[TBL] [Abstract][Full Text] [Related]
12. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
13. A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy.
Lee SY; Yang CY; Peng CL; Wei MF; Chen KC; Yao CJ; Shieh MJ
Biomaterials; 2016 Apr; 86():92-105. PubMed ID: 26896610
[TBL] [Abstract][Full Text] [Related]
14. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
15. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
16. VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer.
Chen J; Sun X; Shao R; Xu Y; Gao J; Liang W
Int J Nanomedicine; 2017; 12():6075-6088. PubMed ID: 28860767
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
18. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer.
Kim SH; Jeong JH; Lee SH; Kim SW; Park TG
J Control Release; 2008 Jul; 129(2):107-16. PubMed ID: 18486981
[TBL] [Abstract][Full Text] [Related]
19. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery.
Egorova A; Shubina A; Sokolov D; Selkov S; Baranov V; Kiselev A
Int J Pharm; 2016 Dec; 515(1-2):431-440. PubMed ID: 27789364
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
